Silence Therapeutics Long Term Debt 2021-2025 | SLN

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Silence Therapeutics long term debt from 2021 to 2025. Long term debt can be defined as the sum of all long term debt fields.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Silence Therapeutics long term debt from 2021 to 2025. Long term debt can be defined as the sum of all long term debt fields.

Related Stocks
Company Name	Market Cap
Chugai Pharmaceutical (CHGCY)	$80.2B
Zoetis (ZTS)	$68.3B
Daiichi Sankyo, - (DSNKY)	$47.1B
Takeda Pharmaceutical (TAK)	$46.9B
BeOne Medicines - (ONC)	$32.3B
Sandoz Group AG (SDZNY)	$26.4B
Summit Therapeutics (SMMT)	$20.8B
Merck (MKKGY)	$17.3B
Shionogi (SGIOY)	$14.5B
United Therapeutics (UTHR)	$13.8B
Neurocrine Biosciences (NBIX)	$13.2B
Orion OYJ (ORINY)	$11.7B
IPSEN (IPSEY)	$10.9B
Stevanato Group S.p.A (STVN)	$7.7B
Corcept Therapeutics (CORT)	$7.3B
Madrigal Pharmaceuticals (MDGL)	$6.8B
Grifols, S.A (GRFS)	$6.8B
Ionis Pharmaceuticals (IONS)	$6.7B
Hikma Pharmaceuticals Plc (HKMPF)	$5.9B
Ono Pharmaceutical (OPHLF)	$5.2B
Soleno Therapeutics (SLNO)	$4.4B
Hypermarcas (HYPMY)	$3.1B
Crinetics Pharmaceuticals (CRNX)	$2.9B
NewAmsterdam Pharma (NAMS)	$2.7B
Catalyst Pharmaceuticals (CPRX)	$2.6B
Procaps Group, S.A (PROCF)	$2.5B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.5B
Centessa Pharmaceuticals (CNTA)	$2.1B
Ocular Therapeutix (OCUL)	$1.9B
BioCryst Pharmaceuticals (BCRX)	$1.8B